From THE DEPARTMENT OF CLINICAL NEUROSCIENCE
Karolinska Institutet, Stockholm, Sweden
COGNITIVE FUNCTION AND
NEUROPHYSIOLOGICAL CORRELATES IN
RELAPSING-REMITTING MULTIPLE SCLEROSIS
Mathias Sundgren
Stockholm 2016
All previously published papers were reproduced with permission from the publisher.
Published by Karolinska Institutet.
Printed by E-PRINT AB
© Mathias Sundgren, 2016
ISBN 978-91-7676-259-2
Cognitive Function and Neurophysiological Correlates in
Relapsing-Remitting Multiple Sclerosis
THESIS FOR DOCTORAL DEGREE (Ph.D.)
By
Mathias Sundgren
Principal Supervisor:
Professor Tom Brismar
Karolinska Institutet
Department of Clinical Neuroscience
Clinical Neurophysiology
Co-supervisors:
Professor Åke Wahlin
Jönköping University
School of Health and Welfare
Institute of Gerontology
Professor Fredrik Piehl
Karolinska Institutet
Department of Clinical Neuroscience
Neuroimmunology
Opponent:
Professor Magnus Vrethem
Linköping University
Department of Clinical and Experimental
Medicine
Division of Neuro and Inflammation Sciences
Examination Board:
Associate Professor Roland Flink
Uppsala University
Department of Neuroscience
Clinical Neurophysiology
Professor Ann-Marie Landtblom
Uppsala University
Department of Neuroscience
Neurology
Professor Agneta Herlitz
Karolinska Institutet
Department of Clinical Neuroscience
Psychology
To Astrid and Branka
ABSTRACT
Impaired cognitive function is a frequent consequence of multiple sclerosis (MS). It
negatively affects vocational status, treatment adherence, physical independence, competence
in activities of daily life, rehabilitation potential, driving safety and quality of life. All papers
in this thesis concern cognitive function in relapsing-remitting MS (RRMS), with emphasis
on clinical and neurophysiological predictors, moderating factors and the effect of
natalizumab (NZ) treatment.
I. The aim of this paper was to identify the strongest clinical predictors for cognitive
impairment in RRMS patients. Patients with RRMS (n=72) and healthy control subjects
(n=89) underwent comprehensive cognitive testing and clinical assessment. Physical
disability (EDSS), fatigue (FSS), somatic and non-somatic components of depression (BDI-S
and BDI-NS), disease progression rate (MSSS), and presence of psychotropic medication
were included in the analysis. Patients had a mean EDSS of 2.7 and disease duration of 9.3
years. Depression and fatigue estimates were significantly higher in patients than in control
subjects (p<0.0001). Cognitive impairment had a prevalence of 30.5% in patients affecting
preferentially executive functions, attention and processing speed. EDSS, FSS, BDI-NS and
BDI-S were significantly correlated with several cognitive domains and global cognitive
function in patients. In regression models, cognitive performance was best predicted by BDINS alone or in combination with EDSS. Exclusion of patients with any psychotropic
medication did not influence the main findings.
II. The objective of paper II was to explore if cognitive impairment in RRMS is associated
with abnormal neural function, and if there is evidence of neural compensatory mechanisms.
The study population described in paper I underwent event-related brain potential (ERP)
recordings with visual and auditory choice reaction tasks. Patients had increased visual P300
amplitude frontally. Auditory and visual P300 amplitude were normal in other brain areas,
and response time (RT) was normal. P300 latency was normal except for an increase in
auditory latency occipitally. Cognitive performance correlated positively with visual and
auditory parietal P300 amplitude in patients (p<0.0001 and p=0.009, respectively) but not in
controls. Global cognitive score had a significantly stronger correlation (negative) with RT in
patients than in controls (intergroup difference for visual stimulation p=0.015, and for
auditory p=0.050). Notably, these associations were not an epiphenomenon of the cognitive
impairment in patients, because parietal P300 amplitude and RT were normal. We concluded
that patients with low P300 amplitude and long RT were more often cognitively impaired.
III. The aim of paper III was to distinguish different mechanisms for cognitive reserve in
RRMS. Thus, we wished to test the cognitive reserve hypothesis in the present study
population. This hypothesis predicts that high premorbid intelligence, as may be estimated
from years of education and vocabulary knowledge, attenuates the effects of disease burden
on cognitive functioning. In this analysis, the normal effects of premorbid intelligence on the
test scores need to be accounted for. Thus we compared the strength of the correlation
between premorbid intelligence and cognitive performance in patients and controls,
respectively. Contrary to the prediction, premorbid intelligence had no stronger effect on
cognition in patients than in controls. This finding contrasted against the results in paper II
where P300 amplitude and RT did have stronger effect on cognitive function in patients than
in controls, i.e. showed features of a reserve against cognitive impairment in patients. The
strongest neurophysiological (visual P300 amplitude and RT) and clinical (EDSS and BDINS) predictors of cognitive function were studied in a hierarchical linear regression model.
P300 amplitude and RT explained 34% of the variance in global cognitive function
(p<0.001). EDSS and BDI-NS added significantly to explained variance, and the final model
accounted for 44% (p<0.001) of the variation. In a separate analysis, we found that the effects
of P300 and RT on cognitive function were not moderated by premorbid intelligence.
IV. The objective of paper IV was to evaluate the cognitive effects of NZ treatment,
compared to patients on stable first-line treatment and healthy control subjects. Fifteen MS
patients (MS-NZ) underwent cognitive testing when starting NZ treatment and were tested
again after one year. They were compared with fifteen MS patients on stable interferon beta
therapy (MS-C) and twelve healthy control subjects (HC) who also were tested twice with an
interval of one year. The effects of NZ on levels of self-reported depression, fatigue, daytime
sleepiness and perceived health were also examined. MS patients (MS-NZ and MS-C) had
significantly lower baseline cognitive performance compared to HC (global score, p=0.002).
At follow-up, both MS-NZ and MS-C had improved significantly in four and five cognitive
domains, respectively, and in global cognitive score (p=0.013 and p<0.001, respectively). HC
improved significantly in three cognitive domains but not in global score. A regression
analysis showed that participants with lower baseline scores had a significantly greater
improvement, compared to those with a better initial performance (p=0.021). There were no
significant changes in depression, fatigue, daytime sleepiness or perceived health in MS-NZ
or MS-C.
Conclusions
Symptoms of depression, especially non-somatic symptoms, and level of physical disability
are the most important clinical risk factors for cognitive impairment in RRMS patients.
General factors such as ERP amplitude and RT are limiting for cognitive function in RRMS
because P300 amplitude and RT have significantly stronger associations with cognitive
performance in patients compared to HC.
High P300 and fast RT reflect a physiological reserve which may be the strongest moderator
of cognitive impairment in RRMS. In contrast, premorbid intelligence does not constitute a
cognitive reserve in RRMS patients.
The observed increase in frontal P300 amplitude suggests activation of compensatory
networks.
There is no evidence of a beneficial effect on cognitive performance after one year of NZ
treatment. Retest effects are significant and are important to recognize in studies of cognitive
performance.
LIST OF SCIENTIFIC PAPERS
I. Sundgren, M., Maurex, L., Wahlin, Å., Piehl, F. and Brismar, T. (2013)
Cognitive impairment has a strong relation to nonsomatic symptoms of
depression in relapsing-remitting multiple sclerosis.
Archives of Clinical Neuropsychology, 28(2), pp. 144-155.
II. Sundgren, M., Nikulin, V. V., Maurex, L., Wahlin, Å., Piehl, F. and
Brismar, T. (2015)
P300 amplitude and response speed relate to preserved cognitive function in
relapsing-remitting multiple sclerosis.
Clinical Neurophysiology, 126(4), pp. 689-697.
III. Sundgren, M., Wahlin, Å., Maurex, L. and Brismar, T. (2015)
Event related potential and response time give evidence for a physiological
reserve in cognitive functioning in relapsing-remitting multiple sclerosis.
Journal of the Neurological Sciences, 356(1-2), pp. 107-112.
IV. Sundgren, M., Piehl, F., Wahlin, Å. and Brismar, T.
Cognitive function did not improve after initiation of natalizumab treatment
in relapsing-remitting multiple sclerosis. A prospective one-year dual
control group study.
Manuscript
Paper I-III are reproduced with the permission from the publishers.
INNEHÅLLSFÖRTECKNING
1
2
3
4
5
6
7
INTRODUCTION........................................................................................................... 1
1.1 Multiple sclerosis................................................................................................... 1
1.2 Cognitive impairment in MS................................................................................. 2
1.3 Imaging and cognitive impairment in MS ............................................................ 3
1.4 Moderating factors of cognitive impairment ........................................................ 4
1.5 Neurophysiological assessment of brain function ................................................ 6
1.5.1 Event-related potentials............................................................................. 6
1.5.2 Event-related potentials and MS ............................................................... 7
1.5.3 Response time ........................................................................................... 7
1.6 Treatment of cognitive dysfunction in MS ........................................................... 7
AIMS OF THE THESIS ................................................................................................. 9
2.1 General aim ............................................................................................................ 9
2.2 Specific aims .......................................................................................................... 9
SUBJECTS AND METHODS .........................................................................................10
3.1 Subjects ................................................................................................................10
3.2 Clinical instruments .............................................................................................10
3.3 Cognitive examination.........................................................................................11
3.4 Neurophysiological investigations ......................................................................13
3.4.1 Recordings ...............................................................................................13
3.4.2 Auditory ERPs.........................................................................................14
3.4.3 Visual ERPs.............................................................................................14
3.4.4 Response time .........................................................................................14
3.5 Calculations and statistics....................................................................................15
3.5.1 Normalization ..........................................................................................15
3.5.2 Missing data ............................................................................................15
3.5.3 Group comparisons, correlations and regression analyses ....................15
3.5.4 Multiple comparisons ..............................................................................15
3.6 Ethical considerations ..........................................................................................16
RESULTS ......................................................................................................................17
4.1 Paper I ..................................................................................................................17
4.2 Paper II .................................................................................................................18
4.3 Paper III................................................................................................................19
4.4 Paper IV ...............................................................................................................20
CONCLUSIONS .............................................................................................................22
5.1 Paper I ..................................................................................................................22
5.2 Paper II and III .....................................................................................................22
5.3 Paper IV ...............................................................................................................22
LIMITATIONS ...............................................................................................................23
DICUSSION AND FUTURE PROSPECTS ....................................................................24
7.1 Clinical risk factors ..............................................................................................24
7.2 Physiological reserve ...........................................................................................25
7.3 Future intervention studies .................................................................................. 26
8 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ SVENSKA.................... 28
9 ACKNOWLEDGEMENTS.......................................................................................... 30
10 REFERENCES .............................................................................................................. 33
LIST OF ABBREVIATIONS
AD
Alzheimer´s Disease
BDI
Beck Depression Inventory
BDI-NS
Beck Depression Inventory, non-somatic items
BDI-S
Beck Depression Inventory, somatic items
BICAMS
Brief International Cognitive Assessment for Multiple
Sclerosis
BVRT-5
Benton Visual Retention Test
CES-D
Center for Epidemiological Studies – Depression scale
CIS
Clinically Isolated Syndrome
CNS
Central nervous system
D-KEFS
Delis-Kaplan Executive Function System
DMT
Disease modifying treatment
EDSS
Kurtzke Expanded Disability Status Scale
EEG
Electroencephalogram
ERP
Event-related potential
ESS
Epworth Sleepiness Scale
fMRI
Functional magnetic resonance imaging
FSMC
Fatigue Scale for Motor and Cognitive functions
FSS
Fatigue Severity Scale
HC
Healthy control group
MRI
Magnetic resonance imaging
MS
Multiple sclerosis
MS-C
Multiple sclerosis control group
MS-NZ
Multiple sclerosis natalizumab group
MSSS
Multiple Sclerosis Severity Score
NZ
Natalizumab
n.s.
Non-significant
P150
Event-related potential with largest positive peak in the
130-200 ms interval from visual stimuli
P300
Event-related potential with largest positive peak in the
200-500 ms interval from visual or auditory stimuli
PH
Perceived health
PPMS
Primary progressive multiple sclerosis
RAVLT
Rey Auditory Verbal Learning Test
RAVLT-recall
Rey Auditory Verbal Learning Test, recall part
RRMS
Relapsing-remitting multiple sclerosis
RT
Response time
S.D.
Standard deviation
SDMT
Symbol Digit Modalities Test
SLDT
Swedish Lexical Decision Test
SPMS
Secondary progressive multiple sclerosis
SRB:1
Synonyms, Reasoning and Block test, part 1 (‘Vocabulary’)
WAIS-III
Wechsler Adult Intelligence Scale – third edition
1 INTRODUCTION
1.1
MULTIPLE SCLEROSIS
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS)
primarily affecting persons between 20-40 years of age. MS is a leading cause of neurologic
disability among young adults in the developed world. Worldwide, there are more than 2.5
million MS patients [1]. In Sweden, the incidence and prevalence of MS has been estimated
to 10.2 and 188.9/100 000/year, respectively, resulting in approximately 17 500 patients, with
a female to male ratio of 2.35:1 [2, 3].
Pathologically, MS is characterized by widespread lesions, or plaques, in the brain and spinal
cord, causing a variable degree of inflammation, gliosis and neurodegeneration. The
pathogenesis involves both the innate and adaptive immune system leading to widespread
focal lymphocytic infiltration. The exact cause of MS is yet unknown. A complex interaction
of genetic and environmental factors which triggers an abnormal immune response is
suggested [4]. Inflammatory lesions primarily affect the myelin sheath causing inhibition of
axonal transmission which eventually leads to irreversible axonal loss. MS is mainly regarded
as a demyelinating disease of the white matter in the brain, but involvement of the cortical
grey matter is also an important element and not restricted to the progressive stages of the
disease [5].
The diagnosis of MS rests on a combination of disease history, clinical signs and defined
paraclinical findings [6]. Depending on the disease course, MS patients are separated into
three subgroups: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and
primary progressive MS (PPMS) [7]. The disease typically presents as RRMS where
neurological symptoms evolve sub-acutely and then persist for days or weeks before they
gradually remit, however, often leaving some permanent residual neurological symptoms.
Neurological deficits depend on the location of the lesions within the CNS but are usually
motor, sensory or visual, or a combination of all. The relapse rate is highly variable between
patients. The degree of residual symptoms tends to increase with reoccurring relapses. After a
variable period of time, most RRMS patients enter a progressive phase where physical
disability gradually increases without clear relapses (SPMS). In PPMS, the disease is
progressive from start. Importantly, in SPMS and PPMS, neuroinflammation is less
pronounced and disease progression is driven mainly by other, less well characterized,
mechanisms [4].
During the last 20 years, an increasing number of effective drugs for MS have become
available. Disease modifying treatment (DMT) has the ability to reduce the frequency of
clinical relapses, the accumulation of neurological disability and the radiological signs of
disease activity [8]. To date, the use of DMT is restricted to patients with RRMS. The list of
currently approved DMTs in Sweden includes interferon beta (1a and 1b), glatiramer acetat,
natalizumab, fingolimod, dimethyl fumarate, teriflunamide and alemtuzumab [9]. Overall, the
1
basic principle of action for DMTs is inhibition of lymphocyte activity, proliferation and/or
migration, thus affecting only the inflammatory component of the disease [8].
1.2
COGNITIVE IMPAIRMENT IN MS
Besides motor, sensory and visual deficits, MS leads to mood and cognitive disturbances. In
the last decades, research in MS has increased remarkably. However, at the beginning of this
research project, the amount of research dedicated to the cognitive field of MS had not
increased equally [10]. Cognitive impairment in MS is frequent, affecting up to 65% of
patients in cross sectional studies [14, 15]. It is detectable at all stages and subtypes of the
disease [16], including patients with clinically isolated syndrome (CIS) [17]. In RRMS, the
prevalence of cognitive dysfunction is estimated to 22-40% [16, 18]. Patients with SPMS or
PPMS tend to have an even higher frequency of cognitive impairment [19]. Cognitive
impairment in MS usually persists and worsens over time [14, 20]. The need for a deeper
understanding of MS-associated cognitive impairment is stressed by its detrimental effects on
many activities of daily life such as physical independence, employment, coping, medication
adherence, symptom management, rehabilitation potential and driving safety [11]. Selfperception of cognitive performance in MS patients is unreliable and not predictive of
objective cognitive functioning [12, 13] and formal testing is therefore necessary.
Cognition is not a uniform entity, but includes many aspects of complex mental functions.
Various domains of cognitive functioning can be affected in MS. Reduced performance has
been demonstrated in information processing speed, attention, executive functions and
memory. Verbal fluency, but not core language abilities, is often reduced in MS. Impaired
information processing speed and learning and memory are often considered the major
cognitive deficits in MS [21].
While there is an overall consensus about the general profile and importance of cognitive
impairment in MS, there is less consensus on clinical risk factors. Previous studies have
found a modest or moderate association between cognitive performance and level of physical
disability [18, 22, 23], but this relationship is likely to be less pronounced or lacking when the
level of physical disability is lower [10]. Cognitive impairment may exist independently of
physical disability [24]. A consistent finding in previous studies has been a weak or absent
correlation between duration of MS and cognitive impairment [15, 18, 21, 23]. However, an
association is likely to emerge when disease duration exceeds 10 years [10]. The speed of
clinical disease progression can be measured with the Multiple Sclerosis Severity Score
(MSSS) which is an algorithm based on disease duration and level of physical disability [25].
To our knowledge, the MSSS has not previously been evaluated regarding its possible
relationship with cognitive performance.
The relationship between depression in MS and cognitive impairment has not been clear [21],
but an association has been demonstrated in adequately powered studies [26] and primarily
between depression and the cognitive domains of information processing speed and executive
functions [27, 28]. Commonly used scales for depression include items rating presence and
2
severity of somatic symptoms which can be confounded by disease related symptoms in
clinical samples such as MS patients. In these depression scales, somatic and non-somatic
items can usually be separated but most prior studies have not made this distinction.
However, in studies where cognitive performance was correlated with the separate
components of depression, a stronger association was reported for the non-somatic symptoms
[29, 30].
Fatigue is a common symptom in patients and an association with decreased information
processing speed has been reported [31]. However, several other studies did not find
subjective fatigue to be associated with cognitive impairment [32, 33].
A concomitant use of CNS-active psychotropic medication against depression, fatigue, pain
and insomnia is often present in MS patients. These drugs may have effects, negative or
positive, on cognitive performance. In studies on cognitive functioning in MS patients,
information regarding the use of psychotropic medication is frequently lacking.
1.3
IMAGING AND COGNITIVE IMPAIRMENT IN MS
Magnetic resonance imaging (MRI) is the most commonly used paraclinical tool to
investigate MS pathology and to monitor disease evolution. Cognitive deficits in MS has
been related to a disconnection syndrome caused by involvement of white matter tracts [34].
However, most studies have shown a modest or moderate association between visible lesions
and cognitive impairment in MS [35]. The overall effect of lesion volume on cognitive
impairment is limited and lesion assessment alone is not considered adequate to assess and
monitor cognitive function in MS patients [35].
With disease progression, white matter abnormalities change from predominantly focal and
periventricular to more subtle and diffuse. Such changes are accompanied by an increase in
the extent of demyelination within the grey matter [36]. Some grey matter atrophy is found
early in the disease course but becomes prominent in SPMS [37] and the rate of brain atrophy
is considered to accelerate around conversion from RRMS to SPMS [38]. As compared to
assessment of lesions, measures of global or regional brain atrophy have a more robust
association with cognitive performance in MS [39, 40]. However, quantification of brain
atrophy has so far not been available in clinical practice. The presence of diffuse damage in
the white and grey matter, as identified with experimental and more advanced MRI
techniques, are likely to be important for the cognitive impairment [35].
Brain cortical activation can be visualized with functional MRI (fMRI). Several fMRI studies
have indicated that cognitive task performance is associated with increased or altered cortical
activation patterns in patients with MS [41]. RRMS patients with normal performance in a
test of processing speed and working memory activated larger frontal cortical areas compared
to healthy control (HC) subjects. In contrast, this increased activity was less pronounced in
RRMS patients with a lower cognitive performance [41].
3
1.4
MODERATING FACTORS OF COGNITIVE IMPAIRMENT
As described, the relationship between measures of disease burden and cognitive outcomes is
incomplete and the amount of explained variance in statistical models remains moderate [35,
42]. This phenomenon is not restricted to MS but is seen in other neurological diseases also.
For example, higher levels of premorbid intelligence and educational attainment may be
factors associated with a slower deterioration in Alzheimer´s disease (AD). This has been
attributed to a larger ‘cognitive reserve’, attenuating the effects of the disease process on
cognitive functioning [43]. More generally, cognitive reserve can be defined as a brain
structure or function that optimizes the individual cognitive performance in the presence of
brain pathology or injury. Because direct measurement of cognitive reserve is not available,
proxy or surrogate variables are used. Premorbid intelligence, as estimated from years of
education or performance in vocabulary tests, is tested as a moderating factor together with
other predictors of cognitive outcomes [44, 45]. Cross-sectional studies in populations of
mixed sub-groups of MS have reported a moderating effect of premorbid intelligence on the
relationship between MRI variables of disease burden and cognitive impairment [46-49]. The
effect of cognitive reserve can be assessed in a correlation analysis between premorbid
intelligence and cognitive test performance. To support the cognitive reserve hypothesis this
correlation needs to be significantly stronger among patients than in healthy individuals [50,
51] (Fig. 1). Previous studies have reported such a finding in MS patients [52, 53]. Cognitive
reserve in MS is however still a novel field of research, and the need for replication has been
stressed [54].
It is important to recognize the pervasive effects of education on cognitive test performance
in normal healthy individuals [55]. Premorbid intelligence may be of clinical importance even
if it does not retard the speed of cognitive decline. Let us assume that there is a certain level
where the cognitive decline becomes critical for work abilities and activities of daily life (Fig.
2). For individuals with high premorbid intelligence at disease onset, it takes longer to reach
this critical level than for those with low premorbid intelligence. This difference may be
thought of as a ‘reserve’ but is not meant with ‘cognitive reserve’.
4
Fig. 1. Schematic illustration of the cognitive reserve hypothesis. The correlation between
premorbid intelligence (e.g. educational attainment) and cognitive performance should be
significantly stronger in the clinical sample (black solid line) than in the normal healthy
sample (black interrupted line).
Fig. 2. Schematic illustration of the cognitive reserve hypothesis in a longitudinal analysis.
The decline in cognitive performance should be slower in patients with high premorbid
intelligence (red solid line) than in patients with low premorbid intelligence (blue solid line).
Note that even in the absence of this phenomenon, patients with high premorbid intelligence
(red interrupted line) will reach a level of clinical impairment (grey solid line) at a later stage
and thus still benefit from a higher premorbid intelligence.
5
1.5
NEUROPHYSIOLOGICAL ASSESSMENT OF BRAIN FUNCTION
1.5.1 Event-related potentials
All mental functions are mediated through highly complex neuronal activity within the CNS.
This is associated with electrical activity causing voltage fluctuations on the scalp which can
be recorded in the electroencephalogram (EEG). Specific fluctuations can be elicited in the
EEG in response to standardized discrimination tasks involving sensory stimuli (events).
Event-related potentials (ERPs) can be elicited when a subject differentiates between two
different stimuli and responds to the target with a button press. The stimuli are usually
auditory (different sounds) or visual (different visual patterns on a screen). The tasks are not
difficult to perform but require the participant´s attention. ERP recordings are non-invasive
and have an excellent temporal but moderate spatial resolution [56].
Different testing paradigms exist. In the odd-ball design, the subject is instructed to respond
only to a predefined infrequent target stimulus in a train of frequent non-target stimuli. In a
choice-reaction task design, the subject responds to both of the different stimuli, with a left or
right hand button press. Each stimulus (visual or auditory) generates a small electrical signal
which is recorded in the EEG. In order to distinguish this signal from the background
spontaneous EEG activity, it is necessary to perform an averaging of repeated events. The
ERPs appear as a series of positive and negative voltage fluctuations (components), which
can be quantified with regard to amplitude and latency [56].
Three main models have been proposed for the mechanisms how ERPs are generated [57].
According to the evoked model, ERPs are created when silent neurons are activated by the
stimulus. Another model suggests a resetting mechanism where neurons with ongoing
oscillatory activity undergo sudden transition to a specific phase due to the stimulus. A third
model proposes that the stimulus induces high frequency oscillations which in turn are
correlated with low frequency activity and a baseline shift. The subsequent signal averaging
cancels the high frequency component, leaving the baseline shifts in the EEG.
ERPs are classified in a standardized manner after polarity (N, negative or P, positive) and
approximate peak latency. The most widely studied ERP is the large positively deflecting
component peaking around 300 ms after the stimulus event and before the motor response
(P300). P300 is generated over widespread bilateral cortical regions and dominates over
centro-parietal scalp regions [58, 59]. There is general agreement that P300 is not a unitary
phenomenon but rather represents distributed neural activity that comprises several
functionally distinct and mutually overlapping subcomponents. E.g., in easy tasks
subcomponents of the P300 add together, whereas in more difficult conditions they diverge
leading to a reduced amplitude [60]. Furthermore, a more frontally dominating component
can be elicited depending on the nature of the stimulus paradigm [61]. The P300 component
is commonly regarded as the neural origin of the cognitive processes related to volitional
detection behavior and the P300 amplitude increases in proportion to the amount of
attentional capacity invested in the event categorization [60]. The amplitude of P300 is also
6
dependent on the nature and presentation of the given stimulus. Character and appearance
probability (such as inter-stimulus interval) of the targets influence the amplitude [61]. P300
latency is considered to measure the time required to detect and evaluate a given stimulus
[62]. Any brain disorder affecting cognitive processes may reduce amplitude and increase
latency of the P300 [63].
Early ERP components, appearing <200 ms after a stimulus, are commonly regarded as
sensory or exogenous in nature with no relation to cognitive processes. However, an
association between early components and cognitive function has been described in diabetes
mellitus [64].
1.5.2 Event-related potentials and MS
Previous research with ERP assessments in MS patients is heterogeneous due to
discrepancies in sample size, clinical characteristics, cognitive testing and EEG electrode
numbers [65, 66]. Most previous ERP-studies have included mixed samples of MS-patients,
including both patients with RRMS and those with progressive subtypes of the disease,
making inferences or generalizations regarding subgroups of MS difficult. These studies have
generally reported reduced amplitude and increased latency of the P300 component [65, 66].
Larger effects on P300 are seen in the SPMS and PPMS, compared to RRMS [67]. Some
studies report normal P300 amplitudes in MS patients, despite reduced cognitive test
performance [68, 69]. In CIS patients with reduced cognitive performance, P300 amplitude
and latency are normal [70].
Few studies have combined MRI and ERP recordings in MS. P300 latency has been reported
to be increased and to be correlated with MRI lesions [71]. In another study, P300 to auditory
and visual stimuli were normal in three groups of MS patients stratified after degree and
distribution of MRI lesions [72]. In MS, early ERP components were found to be both normal
[69, 71] and abnormal [73-76].
1.5.3 Response time
Performance in time-dependent cognitive tests is often reduced in MS patients. The response
time (RT) of auditory and visual target detection can be assessed during ERP recordings but
is frequently lacking in studies with MS patients. RT in ERP stimulation tasks has been
reported to be slower [72, 75] or normal [77] but the studies differ with regard to MS patient
characteristics and type and difficulty of stimuli. Fast RT is associated with better cognitive
abilities in healthy individuals [78]. Similarly, a relationship between RT and measures of
processing speed has been reported in RRMS patients [79]. They found that RT in choice
reaction tasks was a more sensitive measure of impaired information processing in RRMS as
compared to a simple RT task.
1.6
TREATMENT OF COGNITIVE DYSFUNCTION IN MS
There is no proven effective rehabilitation program or symptomatic treatment for MS-related
cognitive dysfunction. Symptomatic drug treatment to ameliorate cognitive impairment in
7
MS patients has been investigated. A randomized clinical trial with donepezil (an acetyl
cholinesterase inhibitor approved for AD) was negative [80]. Furthermore, the evidence from
trials using central stimulants is weak or non-existing [81]. Many studies have reported some
cognitive improvement in MS patients following cognitive rehabilitation programs. However,
the evidence reported in the literature remains inconclusive, mainly due to methodological
weaknesses [82, 83].
All approved DMTs reduce the accumulation of brain damage as measured by MRI and thus
should have the potential to slow or restore cognitive function in patients. However, data is
not abundant regarding the specific effects of DMTs on cognitive functioning in MS. Most
studies report an improvement or less deterioration in patients receiving DMTs. However, the
interpretation of data in clinical trials with DMTs is complicated because cognitive
performance is usually a secondary outcome measure and cognitive testing is often restricted
to a single test [81]. Natalizumab (NZ) is one of the more potent DMTs available. Studies
regarding its effect on cognitive outcome in RRMS have reported beneficial effects, however
often lacking control groups [84-91].
8
2 AIMS OF THE THESIS
2.1
GENERAL AIM
The general aim of this thesis was to identify clinical risk factors and neurophysiological
correlates of cognitive impairment in RRMS patients, and to study the effect of NZ treatment
on cognitive functioning.
2.2
SPECIFIC AIMS
The aim of paper I was to identify the strongest clinical risk factors for cognitive impairment
in RRMS patients. Physical disability, depression and fatigue are known to be interrelated in
MS and may all influence cognitive function. The comparison included the importance of the
disease progression speed vs. physical disability, the somatic vs. non-somatic component of
depression, and the possible confounding effect of psychotropic medication (e.g.
antidepressants).
The aim of paper II was to explore if cognitive impairment in RRMS patients is associated
with abnormal neuronal function, if there is evidence of neural compensatory mechanisms
and if the association between cognitive function and ERP variables is different in patients
compared to HC subjects.
The aim of paper III was to distinguish how different factors influence cognitive function in
RRMS. In particular, we tested if cognitive impairment in RRMS is influenced by premorbid
intelligence, how much of the variance in cognitive function is explained by clinical and
neurophysiological predictors, and if the associations of P300 and RT with cognitive
performance are moderated by premorbid intelligence.
The aim of paper IV was to examine the effects of the first year of NZ treatment, compared
with a control receiving standard DMT, on cognitive functioning in RRMS patients. A
second objective was to study the effects on measures of depression, fatigue, daytime
sleepiness and perceived health.
9
3 SUBJECTS AND METHODS
3.1
SUBJECTS
RRMS is the largest subgroup of MS and the only one in which DMTs are approved. The
degree of cognitive impairment may vary depending on subgroup [19]. For these reasons,
only RRMS patients were included in this research project.
The thesis is based on the results from two sets of data. Dataset 1 (paper I, II and III) is a
cross-sectional analysis including RRMS patients (n=72) and HC subjects (n=89). The
patients were recruited at the Department of Neurology at the Karolinska University Hospital
in Stockholm (Solna) between April 2006 and May 2011. The HC subjects were recruited
randomly by the aid of the Swedish population registry (Statistiska centralbyrån).
Dataset 2 (paper IV) is a longitudinal analysis including RRMS patients (n=30) and HC
subjects (n=12), tested twice with an interval of one year. The participants in dataset 2 were
recruited between February 2010 and June 2012. The HC subjects in paper IV were chosen
from the HC subjects of dataset 1.
3.2
CLINICAL INSTRUMENTS
All patients and control subjects were clinically evaluated. The instruments used for the
different groups are indicated in the list below.
The Kurtzke Expanded Disability Status Scale (EDSS) [92] was used to assess physical
disability in patients. This scale has been designed specifically for MS patients and is the
most frequently and widely used scale to rate physical disability.
Multiple Sclerosis Severity Score (MSSS) [25] was used to rate disease severity. The MSSS
is an algorithm relating the score on EDSS with disease duration.
Beck Depression Inventory (BDI) [93] was used to assess symptoms of depression in
patients and HC subjects in all papers. BDI is a widely used self-report questionnaire for
scoring depressive symptoms, and it is recommended for use in populations with MS [94,
95]. The BDI score was also separated into its non-somatic (BDI-NS, items 1-13), and its
somatic part (BDI-S, items 14-21).
Center for Epidemiologic Studies - Depression (CES-D) [96] is a scale for self-assessment
of depressive symptoms given to patients in paper IV, in addition to the BDI. CES-D is
widely used and has good accuracy for predicting clinical depression in MS [97].
Fatigue Severity Scale (FSS) was used for the assessment of subjective fatigue in patients
and controls in all papers. The nine item FSS is the most widely used scale to rate fatigue in
MS, showing high reliability, validity and internal consistency [98].
10
Fatigue Scale for Motor and Cognitive functions (FSMC) [99] is a scale for rating
subjective fatigue and it is designed specifically for the use in MS patients. It was given to
patients in paper IV.
Epworth Sleepiness Scale (ESS) [100] was used to measure daytime sleepiness in patients in
paper IV.
Perceived health (PH) was evaluated with the first item from the Health Related Quality of
Life Short Form (SF-12®) [101]. It was scored on a Likert scale (1 to 5) where 1 is
“excellent” and 5 is “poor”. PH was evaluated in patients in paper IV.
The scores from CES-D and FSMC may be divided and reported as four (CES-D) or two
(FSMC) subscales [96, 99]. However, due to the limited sample size in paper IV and in order
to reduce the number of comparisons, we included only the total scores. For the same
reasons, only the total BDI score was reported in paper IV.
The HC subjects in paper IV (n=12) had received the BDI and FSS at their first test session
(dataset 1) but not the CES-D, FSMC, ESS and PH. Thus, they were only given the BDI and
FSS at the second evaluation.
3.3
COGNITIVE EXAMINATION
Patients and controls underwent a comprehensive cognitive evaluation covering six cognitive
domains (memory, verbal ability, attention, executive functions, visual perception and
organization and processing speed). The included tests were available in Swedish and could
be administered, after sufficient training, by a non-neuropsychologist. All participants were
tested in a distraction-free and quiet environment. Several tests measure more than one
cognitive ability and were thus included in more than one cognitive domain. The grouping of
tests and subtests into cognitive domains was theoretical and decided after discussion among
the authors of paper I (Table 1). The included tests are listed below.
Benton Visual Retention Test (BVRT-5) (Form C, Administration A) [102]. The task is to
memorize and reproduce visual patterns. Domains: memory, visual perception and
organization.
Rey Auditory Verbal Learning Test (RAVLT and RAVLT-recall) [103]. The task is to
learn and recall a list of words. Domain: memory.
Vocabulary from the Synonyms, Reasoning and Block Test, part 1 (SRB:1) [104, 105]. The
task is to identify correct synonyms. Domain: verbal ability. In paper III, the SRB:1 is treated
as a surrogate marker for premorbid intelligence [55].
Controlled Oral Word Association Test from the Delis-Kaplan Executive Function System
(D-KEFS) [106]. The task is to verbally produce, in 60 sec, as many words as possible,
beginning with a specific letter. Domains: verbal ability, executive functions, processing
speed.
11
Color-Word Interference Test from D-KEFS [106]. The test consists of four timed subtests.
Condition 1 (color naming), condition 2 (word reading), condition 3 (inhibition) and
condition 4 (inhibition and switching). Domains: attention (Condition 1 and 2), executive
functions (Condition 1, 2, 3 and 4).
Trail Making Test from D-KEFS [106]. The test consists of five timed subtests. Condition 1
(visual scanning), condition 2 (number sequencing), condition 3 (letter sequencing), condition
4 (number-letter sequencing) and condition 5 (motor speed). Domains: attention (Condition
1, 2, 3 and 5), executive functions (Condition 1, 2, 3, 4 and 5).
Block Design Test from the Wechsler Adult Intelligence Scale - third edition (WAIS-III)
[107]. The timed task is to reproduce patterns using a set of cubes. Domain: visual perception
and organization.
Digit Span Test (Forward and Backward) from WAIS-III [107]. The task is to verbally
repeat, forward or backward, series of digits. Domains: attention (Forward, Backward and
Total), executive functions (Backward).
Digit Symbol Coding Test from WAIS-III [107]. The task is to fill in as many correct
symbols as possible in 120 sec. Domains: visual perception and organization, processing
speed.
Symbol Search Test from WAIS-III [107]. The task is to correctly complete as many symbol
comparisons as possible in 120 sec. Domains: visual perception and organization, processing
speed.
Additionally, premorbid verbal IQ was assessed by the Swedish Lexical Decision Test
(SLDT) [108] in all HC subjects and in patients in paper IV. The total number of cognitive
test scores was twenty. However, RAVLT and RAVLT-recall were not part of dataset 1
because they were not initially included in the patients´ study protocol. Besides test grouping
into domains, a global score was calculated and included in all papers. The total number of
cognitive test sessions in the present thesis was 218.
12
Cognitive domain
Cognitive tests
Memory
Benton Visual Retention Test
Rey Auditory Verbal Learning Test
Rey Auditory Verbal Learning Test – recall
Verbal ability
Controlled Oral Word Association Test
Vocabulary Test
Attention
Color-Word Interference Test, condition 1 and 2
Digit Span Test, Forward
Digit Span Test, Backward
Digit Span Test, Total
Trail Making Test, condition 1,2,3 and 5
Executive functions
Color-Word Interference Test, condition 1-4
Controlled Oral Word Association Test
Digit Span Test, Backward
Trail Making Test, condition 1-5
Visual perception and organization
Benton Visual Retention Test
Block Design Test
Digit Symbol Coding Test
Symbol Search Test
Processing speed
Controlled Oral Word Association Test
Digit Symbol Coding Test
Symbol Search Test
Global score
All tests, including subtests
Table 1. Cognitive tests and cognitive domains
3.4
NEUROPHYSIOLOGICAL INVESTIGATIONS
3.4.1 Recordings
All patients and HC subjects underwent a neurophysiological investigation which was
conducted in a separately located EEG room, designated for research subjects, at the
Department of Neurophysiology at the Karolinska University Hospital (Solna). The
investigation was usually performed within a few days from the cognitive and clinical
evaluations and in many cases it was performed on the same day. EEG was recorded with a
23-channel EEG amplifier (Nervus Digital Equipment Cephalon, Copenhagen, Denmark).
The EEG silver cap electrodes were placed over both hemispheres according to the 10–20
International System. The participants first underwent a standardized resting EEG followed
13
by auditory and visual choice reaction tasks. The collected neurophysiological data were
auditory and visual ERPs in the two modalities.
The specific procedures regarding test-response epochs, recording reference, ground
electrode, inter-stimulus intervals, eye movements monitoring, sampling rate, post processing
of signals and artifact rejection are detailed in paper II.
3.4.2 Auditory ERPs
Auditory ERPs were recorded during an auditory choice reaction task where the participants
were seated with their eyes closed and were instructed to press response keys with their left
and right index finger upon hearing low and high pitch signals, respectively. The signals were
delivered through a loud speaker device at 65 dB and with a duration of 100 ms. Auditory
ERP data were obtained by averaging trials with low and high pitch, respectively. P300 was
identified as the largest positive peak in the interval 200-500 ms.
3.4.3 Visual ERPs
Visual ERPs were recorded with a visual choice reaction task using Kanizsa images of an
illusory square or a non-square (Fig. 3). The subjects were seated in front of a screen
(distance 150 cm), and instructed to press with their right or left index finger, according to
given instructions, when an illusory square or a non-square was presented. Visual ERP data
were obtained by averaging trials with illusory squares and non-squares, respectively. P300
was identified as the largest positive peak in the interval 200-500 ms. P150 was identified as
the largest positive peak in the interval 130-200 ms.
3.4.4 Response time
Response time (RT) was measured simultaneously with the ERP recordings in the auditory
and visual experiment, respectively. RT was recorded from the onset of the stimulus to the
time for response (button press). RT data were obtained by averaging trials of auditory
stimuli (to both auditory targets) and visual stimuli (to both visual targets), respectively.
Fig. 3. Images for the visual choice reaction task. Kanizsa illusory square (left panel) and
non-square (right panel).
14
3.5
CALCULATIONS AND STATISTICS
3.5.1 Normalization
The cognitive test scores were normalized (z-scored) in order to adjust for the normal effects
of age, sex and education. First a linear regression model of the effects of age on each
cognitive test score, respectively, was calculated in the HC subjects separately for men and
women. The residuals were then used to study the normal effect of education (years in school
and higher education) in a second linear regression model and a final set of residuals was
obtained.
The regression lines obtained in the healthy control group for each test score, respectively,
were used on the patient data to adjust for the effects of age separately for men and women
and education, and the final residuals were obtained for each subject and test. Z-scores were
calculated by dividing the final residuals with the standard deviation (S.D.) of the final
residuals in the healthy controls. In this way the tests scores obtained the same weight and the
cognitive domain scores could be calculated from the mean scores of the included tests. For
each participant, a global score was constructed as the average of the z-scores obtained for all
tests.
ERP variables and RT were normalized to adjust for the normal effects of age and sex,
following the same linear regression procedures described for the cognitive scores. Mean
ERP parameter values were calculated for illusory squares and non-squares, and for low and
high pitch signals, respectively. These calculations resulted in z-scored parameter values in
each electrode position. Similarly, RT parameter values were also z-scored.
3.5.2 Missing data
In dataset 1, missing or excluded cognitive data were replaced with the mean value for each
score in patients and controls, respectively. In dataset 2, missing data were not replaced. Only
complete data, with both a baseline and follow-up value, entered the paired t-test analysis.
3.5.3 Group comparisons, correlations and regression analyses
Values were given as mean ± S.D. Significance level was p<0.05. Differences in means
between groups were tested using t-test. Correlation analyses were performed with ranked
data (Spearman´s correlation). Multiple regression analysis was performed with robust linear
regression. Paper III includes both parametric and non-parametric correlations, as indicated.
In paper IV, baseline group differences were analyzed with ANOVA or Chi-square test.
Other group comparisons at baseline were made with t-test or with Wilcoxon rank sum test in
case of non-normal distributed data. Paired t-test was used to analyze changes in data
between the first and second examination.
3.5.4 Multiple comparisons
To reduce the number of comparisons, cognitive test results were only analyzed on domain
levels and as a global cognitive score. The included regression analyses have primarily used
15
global score as the dependent variable. In paper I, only clinical variables with a significant
effect on the global score were considered to be significant. In paper II the number of
comparisons was reduced by grouping electrode positions in five brain regions: frontal (F3,
F4, F7, F8, Fz, Fp1, Fp2 and Fpz), central (C3, C4 and Cz), parietal (P3, P4 and Pz), temporal
(T3, T4, T5 and T6) and occipital (O1, O2 and Oz). In the correlation analyses between
cognitive performance and ERP variables (amplitude and latency), electrode data from
responses to both targets were analyzed together in the auditory and visual modality,
respectively. The Bonferroni procedure was used to correct for multiple independent
comparisons. In paper II, the cumulative binomial distribution was used for multiple
dependent comparisons because simultaneously recorded EEG electrode data from different
locations are not independent from each other [109].
3.6
ETHICAL CONSIDERATIONS
All subjects were informed about the nature and purpose of the study before consenting to
participate. The protocol was approved by the regional ethics committee (Regionala
etikprövningsnämnden i Stockholm). The study was conducted in accordance with Good
Clinical Practice guidelines and the principles of the Declaration of Helsinki.
16
4 RESULTS
4.1
PAPER I
Sundgren, M., Maurex, L., Wahlin, Å., Piehl, F. and Brismar, T. (2013) Cognitive
impairment has a strong relation to nonsomatic symptoms of depression in relapsingremitting multiple sclerosis. Arch Clin Neuropsychol, 28(2), pp. 144-55.
RRMS patients (n=72) and HC subjects (n=89) were evaluated with a large cognitive test
battery and an extensive clinical assessment. The clinical variables of interest were disease
duration, physical disability (EDSS), disease severity (MSSS), fatigue (FSS), depression
(BDI, BDI-NS, BDI-S) and presence of psychotropic medication (e.g. antidepressants). There
were no significant differences between patients and HC in age (mean 37.9 and 38.2,
respectively) or years of education (mean 13.8 and 14.1, respectively). In patients, mean
disease duration was 9.3 years, EDSS 2.7 and MSSS 4.1. As expected, patients had
significantly more symptoms of depression and fatigue compared to HC (p<0.0001). In
patients, 31.9% had a BDI score ≥ 10 indicating an increased risk of depression. Patients had
a high level of subjective fatigue as 52.8% had an FSS score ≥ 5.
Patients had significantly lower cognitive performance than control subjects (global score 0.71, p<0.0001), affecting preferentially executive functions (-0.92), attention (-0.88),
processing speed (-0.64), and visual perception and organization (-0.49). Cognitive
impairment, defined as z-score < -1.5 in two or more cognitive domains, had a prevalence of
30.5%. Cognitive performance in patients had significant negative correlations (nonparametric) with several of the clinical variables. E.g., global cognitive score correlated with
EDSS (r= -0.36), FSS (r= -0.31) and BDI-NS (r= -0.32). BDI-NS had stronger correlation
with cognitive function than BDI-S. Disease duration and MSSS had no or little association
with cognitive impairment. In HC subjects, cognitive performance did not correlate with FSS,
BDI-NS or BDI-S.
Importantly, several of the clinical variables associated with cognitive impairment in patients
were intercorrelated. E.g., FSS was strongly correlated with EDSS, BDI-NS and BDI-S
(p<0.0001). However, MSSS was not associated with FSS or BDI. Multiple regression
analysis was performed to separate the effects of the clinical risk factors on cognitive function
in patients. BDI-NS had stronger effect than other clinical variables, including BDI (total)
and BDI-S, on cognitive function in all cognitive domains except verbal ability which had no
significant predictor. The strongest relationship was between BDI-NS and executive
functions (p<0.0001, adjusted r2= 0.223) and visual perception and organization (p<0.0001,
adjusted r2= 0.198). Because depression may be secondary to the level of physical disability,
we also performed a hierarchical regression analysis with EDSS as the first predictor. The
model EDSS + BDI-NS resulted in higher adjusted r2 values, as compared to BDI-NS as the
single predictor, in two cognitive domains. A model with EDSS + FSS was not significant in
any cognitive domain. The regression analyses were repeated after exclusion of the RRMS
17
patients (n=25) that were receiving any psychotropic medication. However, the results were
similar.
4.2
PAPER II
Sundgren, M., Nikulin, V. V., Maurex, L., Wahlin, Å., Piehl, F. and Brismar, T. (2015)
P300 amplitude and response speed relate to preserved cognitive function in relapsingremitting multiple sclerosis. Clin Neurophysiol, 126(4), pp. 689-97.
The study population described in paper I also underwent a neurophysiological investigation
with ERP and RT assessments.
Visual ERP
Patients had a significant decrease in P150 amplitude and increase in P150 latency in the
frontal region compared to controls. Patients displayed an increase in the P300 amplitude in
the frontal region. E.g., in the Fpz electrode position the P300 amplitude (illusory square
stimulation) was 8.9 ± 3.9 and 7.4 ± 3.3 µV in patients and controls, respectively (p<0.03).
There were no differences between patients and controls regarding visual P300 amplitudes
over any other brain region. Visual P300 latency was normal in patients.
Auditory ERP
The auditory P300 amplitude in response to both targets was normal in patients. There was a
small but significant increase of auditory P300 latency in five, mainly occipital electrodes, in
the low and high pitch stimulation (p=0.002).
ERP and correlation with cognitive function
The P150 amplitude and latency were not related to cognitive function in patients or control
subjects. Contrary, there were consistent and significant correlations between cognitive
function and P300 amplitude of both stimulation modalities in patients, in contrast to HC. In
the linear correlation analysis between parietal visual P300 amplitude and global cognitive
function the correlation coefficient was 0.44 (p<0.0001) in patients and 0.11 (n.s.) in controls.
The strongest correlations (non-parametric) were seen for visual P300 in the parietal region
(global score, r= 0.51, p<0.0001). P300 amplitude in other brain regions also had significant
correlations with cognitive function, however less strong compared to the parietal P300.
Auditory P300 amplitude correlated significantly with cognitive function in patients, albeit
less so than visual. In HC subjects cognitive performance had a weak correlation (p<0.05)
with visual P300 amplitude in the central region, but not in any other brain region and not
with auditory P300 amplitude. The correlation analyses were repeated after exclusion of the
patients with ongoing psychotropic medication (n=25), as specified in paper I, and the main
findings were similar.
Visual P300 latency in patients was not correlated with global score in patients and controls.
Auditory P300 latency showed a positive correlation with three cognitive domains and the
18
global score. This correlation was strongest in the central region (global score, r= 0.32,
p=0.007). There was no correlation between auditory P300 latency and cognitive
performance in controls. Our finding differed from the findings by Whelan et al. (2010) (see
Errata) who described a negative correlation similar to the association between P300 latency
and cognitive performance in dementia disorders where the latency is increased [63]. Our
patients had normal auditory P300 latency in the central region. A possible explanation for
the present finding is that the P300 often has multiple intra-component peaks in the normal
interval [61]. A selective reduction of the later components would make the peak latency
appear earlier.
Visual and auditory RT
Visual RT was 0.47 ± 0.08 and 0.45 ± 0.07 seconds and auditory RT was 0.62 ± 0.15 and
0.60 ± 0.15 seconds, in patients and controls, respectively (n.s.).
RT and correlation with cognitive function
In linear correlation analysis, visual RT correlated significantly with global cognitive function
in patients (-0.53, p<0.001) and in controls (-0.21, p<0.001). Auditory RT correlated
significantly with global score in patients (-0.40, p<0.001) and in controls (-0.15, p=0.02).
Similar to the results regarding P300, the intergroup difference in strength of correlation was
significant.
In patients, RT correlated significantly with the global score and all cognitive domains except
memory (e.g., visual RT and global score, r= -0.52, p<0.001). In control subjects, significant
correlations between RT and cognitive function were only present for visual RT, and the
strongest association was observed for global score (-0.44, p<0.001).
Subsequently we tested if the identified neurophysiological predictors were associated with
the previously identified strongest clinical risk factors, but there were no significant
correlations.
4.3
PAPER III
Sundgren, M., Wahlin, Å., Maurex, L. and Brismar, T. (2015) Event related potential
and response time give evidence for a physiological reserve in cognitive functioning in
relapsing-remitting multiple sclerosis. J Neurol Sci, 356(1-2), pp. 107-112.
In paper III, we tested the cognitive reserve hypothesis in our sample of RRMS patients,
using demographic data regarding participants´ formal education and level of vocabulary
knowledge (SRB:1). The results were compared to the findings in paper II.
Global cognitive function had a significant positive correlation with education in both
patients (r= 0.102, p=0.007) and controls (r= 0.085, p=0.001). Similarly, global score
correlated with vocabulary knowledge in patients (r= 0.29, p=0.004) and controls (r= 0.23,
p=0.0003). The differences in strength of correlation between groups were however not
19
significant. Similarly, no intergroup differences were detected when the same correlation
analyses were performed for each of the cognitive domains.
The neurophysiological variables with the strongest association with global cognitive
function in patients (visual RT and visual parietal P300 amplitude) and the strongest clinical
predictors (EDSS and BDI-NS), were entered into a hierarchical multiple linear regression
model where P300 and RT were Block 1, EDSS Block 2 and BDI-NS Block 3. The
neurophysiological variables (Block 1) explained most of the variance (adjusted r2 = 0.335).
The clinical predictors (Block 2 and 3) added significant variance, and the final model had an
adjusted r2 of 0.444 (p<0.001). The regression analysis was repeated for the separate
cognitive domains as the dependent variable, respectively. P300 and RT explained most of
the variance (16-29%) in five of six domains. Memory was not predicted by P300 or RT or
any of the clinical predictors.
A possible moderating effect of premorbid intelligence on the association between P300/RT
and cognitive function was tested in hierarchical regression models with global score and the
six cognitive domains as dependent variables, respectively. Education (years) and vocabulary
knowledge, respectively, were tested in Block 1 and P300 and RT, respectively, were tested
in Block 2. The interactions education*P300, education*RT, vocabulary*P300 and
vocabulary*RT were entered in Block 3, respectively. However, none of the interactions
were found to be significant.
4.4
PAPER IV
Sundgren, M., Piehl, F., Wahlin, Å. and Brismar, T. Cognitive function did not improve
after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A
prospective one-year dual control group study. Manuscript
MS patients starting NZ (MS-NZ, n=15), MS controls with stable interferon beta therapy
(MS-C, n=15) and healthy control subjects (HC, n=12) performed cognitive testing twice
with an intertest interval of one year. The effects of NZ on levels of self-reported depression
(BDI, CES-D), fatigue (FSS, FSMC), daytime sleepiness (ESS) and perceived health (PH)
were also examined. There were no differences in age, sex, years of education or verbal IQ
between the three groups. MS patients (MS-NZ and MS-C) had significantly lower baseline
performance in all six cognitive domains and in global cognitive function compared to HC
(global score, p=0.002). However, there were no significant baseline differences between
MS-NZ and MS-C in cognitive performance.
After one year, MS-NZ had improved significantly in memory (p=0.015), verbal ability
(p=0.005), visual perception and organization (p=0.030), processing speed (p=0.003) and in
global score (p=0.013). Similarly, MS-C improved significantly in memory (p=0.016),
attention (p=0.030), executive function (p=0.016), visual perception and organization
(p<0.001), processing speed (p<0.001) and global score (p<0.001). The HC group improved
significantly in verbal ability (p=0.035), visual perception and organization (p=0.002) and
processing speed (p=0.021), but not in the other three cognitive domains or in global
20
cognitive score. Due to these results, we hypothesized that the improvements could be
secondary to a stronger retest effect in subjects with low baseline test performance. A
regression analysis including baseline cognitive z-score and z-score change showed that
participants with lower baseline scores had a significantly greater improvement at follow-up,
compared to those with a better initial performance (Spearman´s rho -0.36, p=0.021).
There was no significant change in depression, fatigue, daytime sleepiness or perceived
health in MS-NZ or MS-C. HC subjects improved significantly in FSS (p=0.031).
21
5 CONCLUSIONS
5.1
PAPER I
Symptoms of depression, especially non-somatic symptoms, and level of physical disability
are the most important clinical predictors of poor cognitive performance in RRMS patients.
Fatigue is not a predictor when controlling for the effects of depression.
Cognitive performance in RRMS is not related to MSSS or treatment with psychotropic
medication.
5.2
PAPER II AND III
P300 and RT have stronger association with cognitive test performance in patients than in
healthy controls. In specific, patients with larger P300 amplitude and faster RT had less
cognitive impairment than those with lower P300 amplitude and RT. For this reason, P300
amplitude and RT may be markers of a physiological reserve for cognitive functioning in
RRMS.
The increase in frontal P300 amplitude in patients may reflect compensatory mechanisms.
The average P300 and RT showed only small differences between patients and controls, and
for that reason they are not sensitive markers of brain dysfunction in RRMS.
The proposed physiological reserve may be the strongest moderator of cognitive impairment
in RRMS. Physiological reserve and clinical risk factors (physical disability and depression)
explain a considerable amount of the variance in cognitive functioning in RRMS. In contrast,
premorbid intelligence does not constitute a cognitive reserve in RRMS.
5.3
PAPER IV
There is no evidence of a beneficial effect of NZ treatment on cognitive functioning across
one year. Significant improvement may be artificial and due to retest effects.
Adequate control groups are essential when evaluating cognitive functioning in intervention
trials in RRMS patients.
22
6 LIMITATIONS
In dataset 1, memory function was restricted to the BVRT-5. It was not a sensitive test to
detect impaired memory in patients, despite being a test of immediate visual memory which
is considered to be vulnerable in MS [21]. In dataset 2, the memory domain also included the
RAVLT and RAVLT-recall. In paper IV, patients had significantly lower performance in
memory, compared to HC.
Reduced eye saccadic initiation time and fine motor control of the hand may negatively
interfere with the performance in written cognitive tests in MS, even in patients with low
EDSS [110]. This could potentially have influenced performance in time-dependent tests.
Depression was assessed with self-report scales. Thus, only subjective symptoms of
depression were evaluated. A clinical diagnosis of depression would have required a deeper
psychiatric interview using standardized major depression criteria. However, both BDI and
CES-D have shown good diagnostic accuracy for depression in MS patients [97, 111].
Anxiety is related to depression but should be regarded as a separate psychological disorder.
However, a separate measure of anxiety symptoms was not included among the clinical
instruments.
Disease burden was only assessed with clinical measures. MRI can provide additional
information regarding lesion volume and brain atrophy.
In Paper III, the cognitive reserve hypothesis was tested using years of education and
vocabulary knowledge as proxies. However, there are other proposed surrogate markers of
cognitive reserve that were not included, such as IQ or questionnaires grading the level of
premorbid cognitive leisure activities. A test of verbal IQ (SLDT) was given to all healthy
control subjects and MS patients entering the longitudinal study, but not to the majority of
MS patients in dataset 1.
In Paper IV, the relatively small numbers per group increased the risk of a type-II error
regarding change in depression, fatigue, daytime sleepiness and perceived health.
23
7 DISCUSSION AND FUTURE PROSPECTS
7.1
CLINICAL RISK FACTORS
We identified depression, especially non-somatic symptoms of depression, and physical
disability as the strongest clinical predictors of cognitive impairment in RRMS. The
separation of the somatic and non-somatic items in the BDI was justified because BDI-NS
had a stronger association than BDI-S with cognitive function in patients. Subjective fatigue
was common in patients but it was not a significant predictor for cognitive impairment when
the effects of EDSS and BDI-NS were included in regression models. Notably, the means of
EDSS and BDI were not high (2.7 and 8.8, respectively). In comparison, the level of fatigue
was high as more than 50% of patients scored ≥5 in the FSS. Our finding that subjective
fatigue is not a prominent predictor of cognitive impairment in MS is in agreement with
previous reports [32, 33]. Similarly, we replicated the finding that disease duration is not
associated with cognitive impairment in MS [15, 18, 21, 23]. Disease progression rate, as
measured with MSSS was also not associated with cognitive impairment in patients.
Furthermore, MSSS was not associated with depression or fatigue.
In MS studies with cognitive outcome measures, the presence of CNS-active psychotropic
drugs with potential effects on cognitive performance is frequently overlooked. However,
psychotropic medication was not a confounding factor in our study. It is important to point
out that the patients receiving psychotropic medication were heterogeneous with regard to
indication, pharmaceutical substances, dosage and possible combinations of drugs.
EDSS is regularly monitored in RRMS patients in contrast to symptoms of depression. The
results point at the importance of evaluating depression, especially non-somatic mood
symptoms, in RRMS patients with cognitive impairment. As a consequence, clinicians should
consider the possibility of reduced cognitive function in clinically depressed patients.
If there is an association between depressive symptoms and cognitive impairment in RRMS,
would cognitive function improve if depression is successfully treated? This has not been
sufficiently studied [27]. One controlled clinical study reported objective cognitive
improvement parallel to improved mood [112], a finding that was not confirmed in a later
study [113]. Despite the overall high prevalence of depression in persons with MS [114],
there is a lack of well designed clinical trials for the treatment of depression in MS patients
[115]. In future such studies, it should be considered that depressed but otherwise physically
healthy individuals have an increased risk of cognitive impairment. Cognitive performance is
not immediately restored after successful anti-depressive treatment [116, 117], not even when
other abilities have returned to normal [118]. This issue relates to the topic regarding
cognitive effects of concomitant psychotropic medication, discussed above. In our material,
antidepressants were the most common psychotropic medication.
24
7.2
PHYSIOLOGICAL RESERVE
A major finding was that cognitive performance in RRMS patients is strongly correlated with
the strength of the electrical brain signal and time for response in choice reaction tasks. These
correlations were absent or weaker in healthy individuals. Importantly, RT and parietal P300
amplitude were normal in patients, and the correlations were not epiphenomena of reduced
cognition. Additionally, P300 and RT were not correlated with EDSS. Similarly, in a
previous study, auditory and visual P300 amplitude were normal and not significantly
different between MS patients stratified according to level and distribution of MRI lesion
volume [72]. The results suggest that RRMS patients rely more than healthy individuals on
their level of brain attentional resources and behavioral response speed, for their cognitive
performance. In other words, high P300 amplitude and fast RT may be protective against
cognitive dysfunction in RRMS.
In contrast, years of education and vocabulary knowledge influenced cognitive test
performance equally in patients and healthy control subjects. Accordingly, premorbid
intelligence did not constitute a cognitive reserve in patients. This is in variance with previous
reports [52, 53]. We do not rule out that educational attainment and vocabulary knowledge
attenuate the degree of cognitive impairment in MS patients with more advanced or severe
disease [53].
A physiological reserve hypothesis can be formulated in the same way as the cognitive
reserve hypothesis. Accordingly, patients should have a stronger correlation between the
physiological reserve variable and cognitive function than healthy individuals. Our results
show that P300 amplitude and RT, in contrast to premorbid intelligence, have this association
with cognitive function in RRMS. We suggest that physiological reserve is as a cognitionrelated neural buffer system that helps patients to compensate for the negative cognitive
effects of MS pathology. Importantly, the physiological reserve explained as much as 34% of
the variance in global cognitive function in RRMS. The combined effect of physiological
reserve, physical disability (EDSS) and depression (BDI-NS) explained 44% of the variance.
The description of a measurable physiological reserve in RRMS is a novel finding and may
help identifying RRMS patients at increased risk of cognitive impairment.
Physiological reserve has similarities with the definition of neural reserve proposed by Stern
et al. [119]. Neural reserve represents the natural inter-individual variability in brain network
efficiency and ability to perform a task. Thus, individuals with higher brain network
efficiency may be better at coping with brain pathology.
Neural compensation is another concept of cognitive reserve and refers to the process by
which individuals suffering from brain pathology use different brain networks, or existing
networks differently, to compensate for the disruption imposed by brain disease [44, 45]. In
paper II we found a small but significant increase in frontal P300 amplitude in RRMS
patients. This finding may correspond to an increased, and possibly compensatory, fMRI
signal previously described in MS patients performing cognitive tasks [41, 120, 121].
25
Previous studies have investigated the degree to which premorbid intelligence moderates the
association between MRI indices of MS pathology and cognitive impairment [47-49]. The
proposed physiological reserve should be tested similarly. Does the level of P300 amplitude
and RT moderate the relationship between brain atrophy (or lesion load) and cognitive
function in RRMS? Ideally, a physiological reserve hypothesis should be tested in a
longitudinal study of sufficient length. Does high P300 amplitude and short RT reduce the
risk of cognitive decline associated with MS? Or conversely, are patients with a lower
physiological reserve at higher risk for cognitive impairment? Identification of patients with
increased risk of cognitive dysfunction has recently been highlighted as an important
challenge in MS [35]. MS typically begins at an earlier age than other common CNS
disorders. Other concurrent dementing medical conditions are rare at this age and normal agerelated cognitive decline is not yet large, which facilitates such studies.
7.3
FUTURE INTERVENTION STUDIES
In the present papers we have compared the findings in the patients with control subjects. In
paper IV, it was shown that after one year, NZ therapy did not improve cognitive function as
compared with the control group of other MS patients. Presumably, the increased test
performance in both MS groups was artificial and due to retest effects that were stronger in
patients with a lower baseline performance. The results underscore the importance of
including control groups when evaluating cognitive outcomes in intervention trials. Learning
or retest effects are seen in several cognitive domains, are largest in young adults, and may be
significant also after many years [122]. Retest effects are not restricted to healthy individuals
as they have been described in a variety of clinical samples including MS-patients [123-125].
Uncontrolled studies on cognitive function have therefore limited value. Besides the need for
control groups, several methods for attenuating or eliminating retest effects have been
proposed, such as alternate forms of tests, standardized massed practice and creation of
reliable change indices. However, there is no consensus on the best method [126]. Contrary to
common belief, alternate forms do not eliminate retest effects [127] and may, if forms are not
psychometrically equivalent, introduce irrelevant variance [126]. Including only healthy
individuals as controls is not likely to be sufficient, since retest effects cannot be assumed to
be equal in magnitude in healthy and clinical samples or in individuals across different ages
[122, 128]. Indeed, paper IV showed that the retest effect was larger in patients with a lower
baseline performance. Regardless these constraints, these aspects need to be addressed in
future studies, especially intervention studies with symptomatic drug treatment or cognitive
rehabilitation programs. Targeted enrollment of MS patients with a lower cognitive reserve,
thus at increased risk of developing cognitive impairment, has been suggested [129].
Regarding the cognitive outcome of DMT interventions, comparable non-intervention patient
control groups can not readily be created, for obvious ethical reasons. If DMT mainly limits
progression, rather than restoring function, a future study on cognitive function would
probably need to extend over several years because the natural rate of progression of
cognitive dysfunction may be slow [14]. Considering the difficulties constructing well
26
designed controlled clinical DMT trials with cognitive outcomes, are there acceptable
alternatives? One option may be large scale observational data, which could be achieved
through MS-registries [130]. However, currently only a single cognitive test (symbol digit
modalities test, SDMT) is regularly monitored, and additional tests may be needed to better
cover the spectrum of cognitive deficits. A three test screening battery, the Brief International
Cognitive Assessment for Multiple Sclerosis (BICAMS), has been proposed to monitor MS
cognitive performance [131]. The BICAMS, which does not require expert skills to
administer, includes two memory tests (verbal and visual, respectively) besides the SDMT.
The findings in the present thesis also suggest that inclusion of relevant moderating variables
would improve the interpretation of cognitive outcomes following DMT interventions.
27
8 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ
SVENSKA
Den övergripande problemställningen i denna avhandling är kognitiv nedsättning vid multipel
skleros (MS). MS är en kronisk sjukdom som drabbar unga vuxna, företrädesvis i åldern 2040 år med övervikt för kvinnor. I Sverige finns ca 18 000 personer med MS. Vid sjukdomen
uppträder återkommande lokaliserade inflammationer (”plack”) inom centrala nervsystemet
vilka kan ge upphov till en rad olika neurologiska symptom såsom gång-, kraft-, känsel- och
synstörningar. En stor andel av MS-patienterna drabbas även av försämrade kognitiva
funktioner. Särskilt ses nedsättning inom processhastighet, minne, uppmärksamhet och
flexibilitets- och organisationsförmåga. MS-patienter med kognitiva problem har en ökad risk
för arbetslöshet och sämre yrkeskarriär, sämre följsamhet mot ordinerad behandling och
sämre upplevd livskvalitet. Inom den största MS-gruppen med s.k. skovvis förlöpande MS
(relapsing-remitting MS, RRMS), uppskattas betydande kognitionssnedsättning föreligga hos
mellan 22-40%.
Frågeställningarna i avhandlingens delarbeten I-III var: Vilka faktorer och sjukdomsuttryck
kan öka risken för att utveckla kognitiv nedsättning vid RRMS? Är det hur länge man haft
sjukdomen, grad av neurologiska bortfall, försämringstakten, grad av depression eller abnorm
uttröttbarhet (s.k. fatigue) som är av störst betydelse?
De första delarbetena baseras på en tvärsnittsstudie av patienter med RRMS (n=72) och friska
kontrollpersoner (n=89). Patienterna undersöktes kliniskt och fick besvara en rad
frågeformulär. Patienter och friska undersöktes med ett kognitivt testbatteri. Hos patienterna
var prestationen signifikant sämre jämfört med de friska. Som förväntat hade patienterna
också betydligt högre förekomst av depression och fatigue än de friska kontrollerna.
Analysen visade att depressionssymptom, ensamt eller i kombination med neurologiska
bortfallssymptom, var de starkaste riskfaktorerna för kognitiv försämring vid RRMS.
Betydelsen av depressionssymptomen var ännu tydligare om man exkluderade de symptom
som berör kroppsliga depressionsuttryck (t.ex. dålig sömn och oro för sitt hälsotillstånd),
eftersom dessa kan vara uttryck för själva grundsjukdomen. Våra fynd är viktiga eftersom de
belyser att depressionssymptom, även måttliga, är kognitivt betydelsefulla och bör
uppmärksammas av behandlande läkare.
Deltagarna testades också med s.k. event-related potentials (ERP) som är en EEG-metod, och
samtidigt mättes reaktionstiden. I synnerhet studerade vi styrkan i en specifik ERP-signal
(P300). Vi fann att sambandet mellan P300 och kognitiv prestationsförmåga var betydligt
starkare i patientgruppen jämfört med friska kontroller. Samma mönster sågs vad gällde
reaktionstiden. Detta betyder att patienter som har, eller förmår upprätthålla, en starkare
hjärnsignal (eller snabbare reaktionstid) var betydligt mindre benägna att uppvisa kognitiv
nedsättning. Detta vittnar om att det finns en fysiologisk kognitiv reservkapacitet som
utnyttjas vid RRMS, som kan förhindra eller minimera kognitiv försämring.
28
Kognitiva reservmekanismer har studerats tidigare, framför allt inom demensforskningen.
Medfödda eller förvärvade faktorer har i viss utsträckning visats kunna skydda personers
kognitiva funktioner i händelse av en sjukdom som drabbar hjärnan. Hög utbildningsnivå och
god s.k. vokabulär kunskap har ansetts vara en sådan faktor, även vid MS. Vi testade denna
hypotes på vårt studiematerial. I sådana jämförelser måste man ta hänsyn till att dessa
faktorer även påverkar testresultatet hos friska försökspersoner, och testdata måste korrigeras
därefter. Vi fann att patienter med högre utbildning och god vokabulär inte hade en mindre
grad av kognitiv nedsättning jämfört de patienter som hade lägre utbildning. Hög utbildning
och vokabulär kunskap utgjorde därmed ingen kognitiv reserv vid RRMS. Detta till skillnad
från hög P300 amplitud och snabb reaktionstid som alltså uppvisade de kännetecken som
karaktäriserar en kognitiv reserv. P300 och reaktionstiden kunde i våra beräkningar förklara
en stor del av risken att utveckla kognitiv nedsättning vid RRMS. Denna reserv har tidigare
inte beskrivits inom MS och kan komma att förbättra möjligheterna att identifiera MSpatienter med högre respektive lägre risk för kognitiv svikt.
Många s.k. bromsmediciner finns idag för behandling av RRMS. En vanlig
förstahandsbehandling vid RRMS är interferon-beta men flera alternativ har tillkommit under
de senaste åren och som inkluderar behandlingar som i mycket hög utsträckning minskar den
inflammatoriska komponenten i sjukdomen. Det har emellertid gjorts få studier som specifikt
utvärderar dessa läkemedels effekter på de kognitiva förmågorna. En av de mest effektiva
bromsmedicinerna är natalizumab (NZ). Vår hypotes i delarbete IV var att NZ-behandling
kunde motverka eller reversera kognitiv försämring vid RRMS. Vi genomförde en
longitudinell studie där en grupp RRMS-patienter (n=15) som startade NZ-behandling
jämfördes med stabila patienter på förstahandsbehandling (n=15) samt friska kontrollpersoner
(n=12). Alla tre grupper testades kognitivt två gånger med ett års mellanrum. I båda MSgrupperna, och i viss utsträckning även också hos de friska kontrollerna, sågs signifikanta
förbättringar efter ett år. NZ-behandlade patienter förbättrades inte mer än den andra MSgruppen. Vi drog slutsatsen att de förbättrade kognitiva testresultaten var s.k.
inlärningseffekter. Vi fann också att inlärningseffekten var starkare hos individer med ett
sämre första resultat. Tidigare kognitionsstudier på NZ har sällan inkluderat kontrollgrupper
och därmed inte observerat denna effekt. Vår slutsats är att NZ inte ger en mätbar kognitiv
förbättring efter ett års behandling. Framtida behandlingsstudier bör ha noggrant definierade
kontrollgrupper, beakta normala inlärningseffekter, löpa över längre tid samt med fördel även
inkludera uppskattningar av deltagarnas kognitiva reservkapacitet.
29
9 ACKNOWLEDGEMENTS
My supervisor, Professor Tom Brismar. This work would not have been accomplished
without your profound knowledge, research curiosity, intellectual brilliance and ever friendly
support. I have appreciated so much all the time and great discussions we had during these
years. Your door was always open. I am lucky to have met such a great researcher - and
friend. Thank you Tom!
My co-supervisors, Professor Åke Wahlin and Professor Fredrik Piehl. Thank you Åke, for
your valuable comments on cognition and the careful examination of my drafts. The
manuscripts always became better after your revision. Fredrik, not just my co-supervisor but
also a fantastic colleague. Thank you for sharing your expert knowledge in multiple sclerosis
and neuroimmunology. You have also been an excellent clinical teacher and we have
discussed many interesting clinical cases during the years.
I am very grateful for all the help from Liselotte Maurex, neuropsychologist and co-author.
Your kind support and education in cognitive test procedures was crucial for this work. It was
a pleasure working with you!
Our work included many EEG recordings – all performed by BMA Britten Winström
Nodemar. A big Thank you Britten, for your friendly ways and skillful work in the EEG lab.
Former colleague Erik Wallström. Thank you for helping me in the very beginning of this
research project.
I wish to thank the staff at the section of neuroinflammation (‘MS-mottagningen’), for
the generous help with finding and recruiting all the patients.
The way I have been able to conduct research at two hospital departments exemplifies a great
research environment. Therefore, I wish to thank former and present head of the Departments
of Neurophysiology and Neurology, respectively: Göran Solders and Lars Hyllienmark,
and Lars-Olof Ronnevi and Magnus Andersson. Thank you for supporting me and
allowing me to spend time on these projects. And thanks Magnus, as chief of residents back
in 2001, for employing me!
Having worked at the Department of Neurology for many years, I am happy to say that I have
many excellent colleagues and friends at the clinic. It is a pleasure working with you! Here, I
mention some.
Per Lindström, my clinical supervisor during my residency, who introduced me to Tom
when I was looking for an interesting research project. Lou Brundin, for her dedication and
spirit. Anne Zachau and Ritva Matell, for their outstanding experience and clinical skills.
Liisa Hopia, Ellen Iacobeus and Sofia Hylin whom I have worked with for many years you are great colleagues and friends. Magnus Thorén, for sharing your stroke knowledge
and being the perfect room-mate!
30
I have the privilege to frequently work with Anders Johansson, Karin Wirdefeldt, Gylvi
Thormar, Thomas Willows, Per Svenningsson and Martin Paucar in the movement
disorder team. Thank you for sharing your knowledge, it is always a pleasure discussing
clinical cases with you. I also want to thank the wonderful PD-nurses Margareth Lundgren
and Karin Persliden for great cooperation.
I seize the opportunity to send my appreciation to my colleagues and friends Olafur
Sveinsson, Erik Lundström and Anders Johansson in our club ‘MSLB’, for the great times
we have discussing literature at different restaurant tables around the town. Thank you for
accepting me as ‘fjärde mannen’!
Also, my former colleagues, for clinical guidance and great fun: Anders Sundqvist, Björn
Hedman, Håkan Persson, Tor Ansved and Sapko Bjelak.
I wish to thank my parents Anne-Cathrine and Peter for all their love and support. Dad,
thanks for proofreading this thesis! My sister Catharina and her family, for all the good
times. My brother Christoffer, for all the fun we had together as kids. My wonderful
godparents Dag and Lisbeth, cousins Erik and Nanna with family. Ankica and Mišo, thank
you for your generosity, I am looking forward to Stomorska!
And to all friends outside the medical world - thank you - you mean a lot to me.
Above all I want to thank my partner Branka, you are one of a kind. You have encouraged
and supported me immensely. Last but not least, the most precious in our life, Astrid. I
would not find motivation without you two.
This work was supported by research grants from the Montel Williams MS Foundation and
Stockholm County Council (Stockholms Läns Landsting).
Finally, my sincere appreciation to all study participants who volunteered to be part of these
studies.
31
10 REFERENCES
[1] Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis
epidemiology. Lancet Neurology. 2010;9:520-32.
[2] Ahlgren C, Oden A, Lycke J. High nationwide prevalence of multiple sclerosis in
Sweden. Multiple Sclerosis Journal. 2011;17:901-8.
[3] Ahlgren C, Oden A, Lycke J. High nationwide incidence of multiple sclerosis in Sweden.
PLoS One. 2014;9:e108599.
[4] Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune
responses in the course of multiple sclerosis. Lancet Neurology. 2015;14:406-19.
[5] Calabrese M, Rinaldi F, Mattisi I, Grossi P, Favaretto A, Atzori M, et al. Widespread
cortical thinning characterizes patients with MS with mild cognitive impairment. Neurology.
2010;74:321-8.
[6] Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic
Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Annals of
Neurology. 2011;69:292-302.
[7] Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72 Suppl
1:1-5.
[8] Piehl F. A changing treatment landscape for multiple sclerosis: challenges and
opportunities. J Intern Med. 2014;275:364-81.
[9] Läkemedelsbehandling av multipel skleros (MS) – behandlingsrekommendation.
Information från Läkemedelsverket 6:2015.
[10] Prakash RS, Snook EM, Lewis JM, Motl RW, Kramer AF. Cognitive impairments in
relapsing-remitting multiple sclerosis: a meta-analysis. Multiple Sclerosis. 2008;14:1250-61.
[11] Langdon DW. Cognition in multiple sclerosis. Current Opinion in Neurology.
2011;24:244-9.
[12] Julian L, Merluzzi NM, Mohr DC. The relationship among depression, subjective
cognitive impairment, and neuropsychological performance in multiple sclerosis. Multiple
Sclerosis. 2007;13:81-6.
[13] Middleton LS, Denney DR, Lynch SG, Parmenter B. The relationship between
perceived and objective cognitive functioning in multiple sclerosis. Archives of Clinical
Neuropsychology. 2006;21:487-94.
[14] Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: A
review of cross-sectional and longitudinal studies. J Neurol Sci. 2006;245:41-6.
[15] Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis.
I. Frequency, patterns, and prediction. Neurology. 1991;41:685-91.
[16] Potagas C, Giogkaraki E, Koutsis G, Mandellos D, Tsirempolou E, Sfagos C, et al.
Cognitive impairment in different MS subtypes and clinically isolated syndromes. J Neurol
Sci. 2008;267:100-6.
33
[17] Khalil M, Enzinger C, Langkammer C, Petrovic K, Loitfelder M, Tscherner M, et al.
Cognitive impairment in relation to MRI metrics in patients with clinically isolated
syndrome. Multiple Sclerosis. 2011;17:173-80.
[18] Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, et al. Cognitive
impairment and its relation with disease measures in mildly disabled patients with relapsingremitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple
Sclerosis (COGIMUS) study. Multiple Sclerosis. 2009;15:779-88.
[19] Huijbregts SCJ, Kalkers NF, de Sonneville LMJ, de Groot V, Polman CH. Cognitive
impairment and decline in different MS subtypes. J Neurol Sci. 2006;245:187-94.
[20] Bagert B, Camplair P, Bourdette D. Cognitive dysfunction in multiple sclerosis - Natural
history, pathophysiology and management. CNS Drugs. 2002;16:445-55.
[21] Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet
Neurology. 2008;7:1139-51.
[22] Beatty WW, Goodkin DE, Hertsgaard D, Monson N. Clinical and demographic
predictors of cognitive performance in multiple sclerosis – do diagnostic type, disease
duration, and disability matter. Archives of Neurology. 1990;47:305-8.
[23] Lynch SG, Parmenter BA, Denney DR. The association between cognitive impairment
and physical disability in multiple sclerosis. Multiple Sclerosis. 2005;11:469-76.
[24] Cobble N. The rehabilitative management of patients with multiple sclerosis. J Neurol
Rehab. 1992;6:141-5.
[25] Roxburgh R, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al.
Multiple sclerosis severity score - Using disability and disease duration to rate disease
severity. Neurology. 2005;64:1144-51.
[26] Arnett PA, Barwick FH, Beeney JE. Depression in multiple sclerosis: Review and
theoretical proposal. J Internat Neuropsychol Soc. 2008;14:691-724.
[27] Feinstein A. Mood disorders in multiple sclerosis and the effects on cognition. J Neurol
Sci. 2006;245:63-6.
[28] Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. Journal of
Neurology Neurosurgery and Psychiatry. 2005;76:469-75.
[29] Arnett PA, Higginson CI, Voss WD, Wright B, Bender WI, Wurst JM, et al. Depressed
mood in multiple sclerosis: Relationship to capacity-demanding memory and attentional
functioning. Neuropsychology. 1999;13:434-46.
[30] Beatty WW. Cognitive dysfunction in multiple sclerosis: natural history and impact on
productive living. Italian Journal of Neurological Sciences. 1998;19:S381-S7.
[31] Andreasen AK, Spliid PE, Andersen H, Jakobsen J. Fatigue and processing speed are
related in multiple sclerosis. European Journal of Neurology. 2010;17:212-8.
[32] Bol Y, Duits AA, Hupperts RMM, Vlaeyen JWS, Verhey FRJ. The psychology of
fatigue in patients with multiple sclerosis: A review. Journal of Psychosomatic Research.
2009;66:3-11.
34
[33] Morrow SA, Weinstock-Guttman B, Munschauer FE, Hojnacki D, Benedict RHB.
Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: crosssectional and longitudinal analysis. Multiple Sclerosis. 2009;15:998-1005.
[34] Calabrese P, Penner IK. Cognitive dysfunctions in multiple sclerosis--a "multiple
disconnection syndrome"? J Neurol. 2007;254 Suppl 2:Ii18-21.
[35] Rocca MA, Amato MP, De Stefano N, Enzinger C, Geurts JJ, Penner IK, et al. Clinical
and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurology.
2015;14:302-17.
[36] Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, et
al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain.
2005;128:2705-12.
[37] Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, et al.
Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol.
2008;64:247-54.
[38] Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a
longitudinal study. Ann Neurol. 2008;64:255-65.
[39] Filippi M, Rocca MA, Benedict RHB, DeLuca J, Geurts JJG, Rombouts S, et al. The
contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology.
2010;75:2121-8.
[40] Grassiot B, Desgranges B, Eustache F, Defer G. Quantification and clinical relevance of
brain atrophy in multiple sclerosis: a review. J Neurol. 2009;256:1397-412.
[41] Mainero C, Caramia F, Pozzilli C, Pisani A, Pestalozza I, Borriello G, et al. fMRI
evidence of brain reorganization during attention and memory tasks in multiple sclerosis.
Neuroimage. 2004;21:858-67.
[42] Benedict RHB, Zivadinov R. Risk factors for and management of cognitive dysfunction
in multiple sclerosis. Nat Rev Neurol. 2011;7:332-42.
[43] Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurology.
2012;11:1006-12.
[44] Barulli D, Stern Y. Efficiency, capacity, compensation, maintenance, plasticity:
emerging concepts in cognitive reserve. Trends in Cognitive Sciences. 2013;17:502-9.
[45] Stern Y. Cognitive reserve. Neuropsychologia. 2009;47:2015-28.
[46] Modica CM, Bergsland N, Dwyer MG, Ramasamy DP, Carl E, Zivadinov R, et al.
Cognitive reserve moderates the impact of subcortical gray matter atrophy on
neuropsychological status in multiple sclerosis. Multiple Sclerosis. 2016;22:36-42.
[47] Pinter D, Sumowski J, DeLuca J, Fazekas F, Pichler A, Khalil M, et al. Higher
Education Moderates the Effect of T2 Lesion Load and Third Ventricle Width on Cognition
in Multiple Sclerosis. PLoS One. 2014;9.
[48] Sumowski JF, Chiaravalloti N, Wylie G, DeLuca J. Cognitive reserve moderates the
negative effect of brain atrophy on cognitive efficiency in multiple sclerosis. J Internat
Neuropsychol Soc. 2009;15:606-12.
35
[49] Sumowski JF, Wylie GR, Chiaravalloti N, DeLuca J. Intellectual enrichment lessens the
effect of brain atrophy on learning and memory in multiple sclerosis. Neurology.
2010;74:1942-5.
[50] Stern Y. What is cognitive reserve? Theory and research application of the reserve
concept. J Internat Neuropsychol Soc. 2002;8:448-60.
[51] Sumowski JF, Leavitt VM. Cognitive reserve in multiple sclerosis. Multiple Sclerosis
Journal. 2013;19:1122-7.
[52] Sumowski JF, Chiaravalloti N, DeLuca J. Cognitive reserve protects against cognitive
dysfunction in multiple sclerosis. J Clin Exp Neuropsychol. 2009;31:913-26.
[53] Sumowski JF, Chiaravalloti N, Leavitt VM, DeLuca J. Cognitive reserve in secondary
progressive multiple sclerosis. Multiple Sclerosis Journal. 2012;18:1454-8.
[54] Benedict RHB, Morrow SA, Guttman BW, Cookfair D, Schretlen DJ. Cognitive reserve
moderates decline in information processing speed in multiple sclerosis patients. J Internat
Neuropsychol Soc. 2010;16:829-35.
[55] Lezak MD. Neuropsychological assessment. Oxford: Oxford University Press; 2004.
[56] Duncan CC, Barry RJ, Connolly JF, Fischer C, Michie PT, Naatanen R, et al. Eventrelated potentials in clinical research: Guidelines for eliciting, recording, and quantifying
mismatch negativity, P300, and N400. Clinical Neurophysiology. 2009;120:1883-908.
[57] Cooray GK. Effect of Diabetes Mellitus on Human Brain Function. Thesis. Stockholm:
Karolinska Institutet; 2010.
[58] Juckel G, Karch S, Kawohl W, Kirsch V, Jager L, Leicht G, et al. Age effects on the
P300 potential and the corresponding fMRI BOLD-signal. Neuroimage. 2012;60:2027-34.
[59] Pfefferbaum A, Ford JM, Wenegrat BG, Roth WT, Kopell BS. Clinical application of
the P3 component of event-related potentials. 1. Normal aging. Electroencephalography and
Clinical Neurophysiology. 1984;59:85-103.
[60] Kok A. On the utility of P3 amplitude as a measure of processing capacity.
Psychophysiology. 2001;38:557-77.
[61] Polich J. Updating p300: An integrative theory of P3a and P3b. Clinical
Neurophysiology. 2007;118:2128-48.
[62] Kutas M, McCarthy G, Donchin E. Augmenting mental chronometry: the P300 as a
measure of stimulus evaluation time. Science (New York, NY). 1977;197:792-5.
[63] Polich J, Herbst KL. P300 as a clinical assay: rationale, evaluation, and findings. Internat
J Psychophysiol. 2000;38:3-19.
[64] Cooray GK, Maurex L, Brismar T. Cognitive impairment correlates to low auditory
event-related potential amplitudes in type 1 diabetes. Psychoneuroendocrinology.
2008;33:942-50.
[65] Leocani L, Gonzalez-Rosa JJ, Comi G. Neurophysiological correlates of cognitive
disturbances in multiple sclerosis. Neurological Sciences. 2010;31:249-53.
[66] Magnano I, Aiello I, Piras MR. Cognitive impairment and neurophysiological correlates
in MS. J Neurol Sci. 2006;245:117-22.
36
[67] Ellger T, Bethke F, Frese A, Luettmann RJ, Buchheister A, Ringelstein EB, et al. Eventrelated potentials in different subtypes of multiple sclerosis - a cross-sectional study. J Neurol
Sci. 2002;205:35-40.
[68] Pokryszko-Dragan A, Zagrajek M, Slotwinski K, Gruszka E, Bilinska M, Podemski R.
Neuropsychological testing and event-related potentials in the assessment of cognitive
performance in the patients with multiple sclerosis - a pilot study. Clin Neurol Neurosurg.
2009;111:503-6.
[69] van Dijk JG, Jennekensschinkel A, Caekebeke JFV, Singh A, Zwinderman AH. What is
the validity of an abnormal evoked or event-related potential in MS? Auditory and visual
evoked and event-related potentials in multiple sclerosis patients and normal subjects. J
Neurol Sci. 1992;109:11-7.
[70] Kocer B, Unal T, Nazliel B, Biyikli Z, Yesilbudak Z, Karakas S, et al. Evaluating subclinical cognitive dysfunction and event-related potentials (P300) in clinically isolated
syndrome. Neurological Sciences. 2008;29:435-44.
[71] Honig LS, Ramsay RE, Sheremata WA. Event-related potential P300 in multiple
sclerosis. Relation to magnetic resonance imaging and cognitive impairment. Archives of
Neurology. 1992;49:44-50.
[72] Sailer M, Heinze HJ, Tendolkar I, Decker U, Kreye O, v Rolbicki U, et al. Influence of
cerebral lesion volume and lesion distribution on event-related brain potentials in multiple
sclerosis. J Neurol. 2001;248:1049-55.
[73] Aminoff JC, Goodin DS. Long-latency cerebral event-related potentials in multiple
sclerosis. Journal of Clinical Neurophysiology. 2001;18:372-7.
[74] Newton MR, Barrett G, Callanan MM, Towell AD. Cognitive event-related potentials in
multiple sclerosis. Brain. 1989;112:1637-60.
[75] Pelosi L, Geesken JM, Holly M, Hayward M, Blumhardt LD. Working memory
impairment in early multiple sclerosis - Evidence from an event-related potential study of
patients with clinically isolated myelopathy. Brain. 1997;120:2039-58.
[76] Whelan R, Lonergan R, Kiiski H, Nolan H, Kinsella K, Bramham J, et al. A high-density
ERP study reveals latency, amplitude, and topographical differences in multiple sclerosis
patients versus controls. Clinical Neurophysiology. 2010;121:1420-6.
[77] Kiiski H, Reilly RB, Lonergan R, Kelly S, O'Brien M, Kinsella K, et al. Change in
PASAT performance correlates with change in P3 ERP amplitude over a 12-month period in
multiple sclerosis patients. J Neurol Sci. 2011;305:45-52.
[78] Deary IJ, Der G, Ford G. Reaction times and intelligence differences - A populationbased cohort study. Intelligence. 2001;29:389-99.
[79] Tombaugh TN, Berrigan LI, Walker LAS, Freedman MS. The Computerized Test of
Information Processing (CTIP) Offers an Alternative to the PASAT for Assessing Cognitive
Processing Speed in Individuals With Multiple Sclerosis. Cognitive and Behavioral
Neurology. 2010;23:192-8.
[80] Krupp LB, Christodoulou C, Melville P, Scherl WF, Pai LY, Muenz LR, et al.
Multicenter randomized clinical trial of donepezil for memory impairment in multiple
sclerosis. Neurology. 2011;76:1500-7.
37
[81] Amato MP, Langdon D, Montalban X, Benedict RHB, DeLuca J, Krupp LB, et al.
Treatment of cognitive impairment in multiple sclerosis: position paper. J Neurol.
2013;260:1452-68.
[82] Mitolo M, Venneri A, Wilkinson ID, Sharrack B. Cognitive rehabilitation in multiple
sclerosis: A systematic review. J Neurol Sci. 2015;354:1-9.
[83] Rosti-Otajarvi EM, Ham alainen PI. Neuropsychological rehabilitation for multiple
sclerosis. Cochrane Database Syst Rev. 2014.
[84] Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, Goretti B, et al. Impact
of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A
Prospective, Open-Label, Two Years Observational Study. PLoS One. 2012;7:7.
[85] Kunkel A, Fischer M, Faiss J, Dahne D, Kohler W, Faiss JH. Impact of natalizumab
treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis.
Frontiers in Neurology. 2015;6:97.
[86] Lang C, Reiss C, Maurer M. Natalizumab May Improve Cognition and Mood in
Multiple Sclerosis. European Neurology. 2012;67:162-6.
[87] Mattioli F, Stampatori C, Bellomi F, Scarpazza C, Capra R. Natalizumab Significantly
Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression
and Preliminary MRI Findings. PLoS One. 2015;10:10.
[88] Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in
patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up
study. Neurological Sciences. 2011;32:83-8.
[89] Morrow SA, O'Connor PW, Polman CH, Goodman AD, Kappos L, Lublin FD, et al.
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening
questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Multiple Sclerosis.
2010;16:1385-92.
[90] Portaccio E, Stromillo ML, Goretti B, Hakiki B, Giorgio A, Rossi F, et al. Natalizumab
may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis:
a prospective, non-randomized pilot study. European Journal of Neurology. 2013;20:986-90.
[91] Wilken J, Kane RL, Sullivan CL, Gudesblatt M, Lucas S, Fallis R, et al. Changes in
Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with
Natalizumab: The ENER-G Study. International Journal of MS Care. 2013;15:120-8.
[92] Kurtzke JF. Rating neurologic impairment in multiple sclerosis – an expanded disability
status scale (EDSS). Neurology. 1983;33:1444-52.
[93] Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression
Inventory – 25 years of evaluation. Clinical Psychology Review. 1988;8:77-100.
[94] Arnett P, Ben-Zacharia A, Benedict R, Bobholz J, Caruso L, Chelune G, et al. The
Goldman Consensus statement on depression in multiple sclerosis. Multiple Sclerosis.
2005;11:328-37.
[95] Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB, et al. Evidence-based
guideline: assessment and management of psychiatric disorders in individuals with MS:
report of the Guideline Development Subcommittee of the American Academy of Neurology.
Neurology. 2014;82:174-81.
38
[96] Radloff LS. The CES-D scale: A self report depression scale for research in the general
population. Applied Psychological Measurements. 1977;1:385-401.
[97] Patten SB, Burton JM, Fiest KM, Wiebe S, Bulloch AG, Koch M, et al. Validity of four
screening scales for major depression in MS. Multiple Sclerosis. 2015;21:1064-71.
[98] Krupp LB, Larocca NG, Muirnash J, Steinberg AD. The Fatigue Severity Scale –
application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of
Neurology. 1989;46:1121-3.
[99] Penner IK, Raselli C, Stocklin M, Opwis K, Kappos L, Calabrese P. The Fatigue Scale
for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess
multiple sclerosis-related fatigue. Multiple Sclerosis. 2009;15:1509-17.
[100] Johns MW. A new method for measuring daytime sleepiness – the Epworth Sleepiness
Scale. Sleep. 1991;14:540-5.
[101] Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction
of scales and preliminary tests of reliability and validity. Medical Care. 1996;34:220-33.
[102] Sivan AB. Benton Visual Retention Test - Fifth Edition. San Antonio, TX: The
Psychological Corporation; 1992.
[103] Schmidt M. Rey Auditory and Verbal Learning Test. A handbook. Los Angeles:
Western Psychological Services; 1996.
[104] Dureman I, Sälde H. Psykometriska och experimentalpsykologiska metoder för klinisk
tillämpning: Studies in psychometric and experimental methods for the clinical evaluation of
mental functioning. Stockholm: Almqvist & Wiksell; 1959.
[105] Psykologiförlaget. Manual for the Dureman-Sälde tests. Stockholm: Psykologiförlaget
AB; 1971.
[106] Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System (D-KEFS).
San Antonio, TX: The Psychological Corporation; 2001.
[107] Wechsler D. Wechsler Adult Intelligence Scale - Third Edition. San Antonio, TX: The
Psychological Corporation; 1997.
[108] Almkvist O, Adveen M, Henning L, Tallberg IM. Estimation of premorbid cognitive
function based on word knowledge: The Swedish Lexical Decision Test (SLDT).
Scandinavian Journal of Psychology. 2007;48:271-9.
[109] Montez T, Poil SS, Jones BF, Manshanden I, Verbunt JP, van Dijk BW, et al. Altered
temporal correlations in parietal alpha and prefrontal theta oscillations in early-stage
Alzheimer disease. Proc Natl Acad Sci USA. 2009;106:1614-9.
[110] Nygaard GO, de Rodez Benavent SA, Harbo HF, Laeng B, Sowa P, Damangir S, et al.
Eye and hand motor interactions with the Symbol Digit Modalities Test in early multiple
sclerosis. Multiple Sclerosis and Related Disorders. 2015;4:585-9.
[111] Fischer A, Fischer M, Nicholls RA, Lau S, Poettgen J, Patas K, et al. Diagnostic
accuracy for major depression in multiple sclerosis using self-report questionnaires. Brain
and Behavior. 2015;5:e00365.
39
[112] Rodgers D, Khoo K, MacEachen M, Oven M, Beatty WW. Cognitive therapy for
multiple sclerosis: a preliminary study. Alternative Therapies in Health and Medicine.
1996;2:70-4.
[113] Kinsinger SW, Lattie E, Mohr DC. Relationship Between Depression, Fatigue,
Subjective Cognitive Impairment, and Objective Neuropsychological Functioning in Patients
With Multiple Sclerosis. Neuropsychology. 2010;24:573-80.
[114] Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, et al. The
incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review.
Multiple Sclerosis Journal. 2015;21:305-17.
[115] Koch MW, Glazenborg A, Uyttenboogaart M, Mostert J, De Keyser J. Pharmacologic
treatment of depression in multiple sclerosis. Cochrane Database Syst Rev. 2011.
[116] Godard J, Baruch P, Grondin S, Lafleur MF. Psychosocial and neurocognitive
functioning in unipolar and bipolar depression: a 12-month prospective study. Psychiatry
Research. 2012;196:145-53.
[117] Preiss M, Kucerova H, Lukavsky J, Stepankova H, Sos P, Kawaciukova R. Cognitive
deficits in the euthymic phase of unipolar depression. Psychiatry Research. 2009;169:235-9.
[118] Airaksinen E, Wahlin Å, Larsson M, Forsell Y. Cognitive and social functioning in
recovery from depression: results from a population-based three-year follow-up. Journal of
Affective Disorders. 2006;96:107-110.
[119] Stern Y, Habeck C, Moeller J, Scarmeas N, Anderson KE, Hilton HJ, et al. Brain
networks associated with cognitive reserve in healthy young and old adults. Cerebral Cortex.
2005;15:394-402.
[120] Audoin B, Duong MV, Ranjeva JP, Ibarrola D, Malikova I, Confort-Gouny S, et al.
Magnetic resonance study of the influence of tissue damage and cortical reorganization on
PASAT performance at the earliest stage of multiple sclerosis. Human Brain Mapping.
2005;24:216-28.
[121] Staffen W, Mair A, Zauner H, Unterrainer J, Niederhofer H, Kutzelnigg A, et al.
Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory
cortical activation during an attention task. Brain. 2002;125:1275-82.
[122] Salthouse TA, Schroeder DH, Ferrer E. Estimating retest effects in longitudinal
assessments of cognitive functioning in adults between 18 and 60 years of age. Dev Psychol.
2004;40:813-22.
[123] Jasperse B, Vrenken H, Sanz-Arigita E, de Groot V, Smith SM, Polman CH, et al.
Regional brain atrophy development is related to specific aspects of clinical dysfunction in
multiple sclerosis. Neuroimage. 2007;38:529-37.
[124] Jonsson A, Andresen J, Storr L, Tscherning T, Sorensen PS, Ravnborg M. Cognitive
impairment in newly diagnosed multiple sclerosis patients: A 4-year follow-up study. J
Neurol Sci. 2006;245:77-85.
[125] Solari A, Radice D, Manneschi L, Motti L, Montanari E. The multiple sclerosis
functional composite: different practice effects in the three test components. J Neurol Sci.
2005;228:71-4.
40
[126] Jones RN. Practice and retest effects in longitudinal studies of cognitive functioning.
Alzheimer's & Dementia. (editorial). 2015;1:101-2.
[127] Beglinger LJ, Gaydos B, Tangphao-Daniels O, Duff K, Kareken DA, Crawford J, et al.
Practice effects and the use of alternate forms in serial neuropsychological testing. Archives
of Clinical Neuropsychology. 2005;20:517-29.
[128] Seidenberg M, O'Leary DS, Giordani B, Berent S, Boll TJ. Test-retest IQ changes of
epilepsy patients: assessing the influence of practice effects. Journal of Clinical
Neuropsychology. 1981;3:237-55.
[129] Sumowski JF. Cognitive reserve as a useful concept for early intervention research in
multiple sclerosis. Frontiers in Neurology. 2015;6:5.
[130] Holmen C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, et al. A
Swedish national post-marketing surveillance study of natalizumab treatment in multiple
sclerosis. Multiple Sclerosis Journal. 2011;17:708-19.
[131] Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, et al.
Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis
(BICAMS). Multiple Sclerosis. 2012;18:891-8.
41